Robert J. Samuelson
Obama administration officials have repeatedly emphasized the need to "bend the
curve" of health-care costs. Reducing increases in health spending, they
argued, was essential to controlling future federal budget deficits and making
insurance affordable for most Americans. Now, in the first comprehensive
evaluation by a government agency of one of the major congressional health-reform bills, analysts find that
it does bend the cost curve—in the wrong direction. The study of H.R. 3200, as reported by the House Ways and Means Committee, concludes
that the legislation would raise total national health spending by $750 billion
over the decade from 2010 to 2019.
The study was done by Richard Foster, chief
actuary of the Centers for Medicare and Medicaid Services, an arm of the
Department of Health and Human Services. CMS's Office of the Actuary, like the
Congressional Budget Office, is often asked to present independent,
nonpartisan estimates of major health-care proposals. In its study, CMS finds
that the Ways and Means Committee bill, one of three major bills in the House,
would dramatically reduce the number of uninsured Americans, from an estimated
57 million in 2019 to 23 million. But this expansion of insurance coverage
"would typically result in a fairly substantial increase in the utilization of
health-care services, with a corresponding impact on total health
expenditures."
The $750 billion spending shift over the
decade would represent a 2.1 percent gain, but the size of the increases rises
in out years. In 2019, for example, total national health spending was
projected to be 2.7 percent higher—$4.796 trillion, or 21.3 percent of gross domestic product. Without the legislation, CMS estimated, total national health
spending would be $4.671 trillion, or 20.8 percent of GDP.
The study doubted that many of the bill's
provisions designed to reduce overall health spending would have much effect.
These include greater use of prevention and "wellness" programs and more
emphasis on "comparative effectiveness research"—limiting treatments to those
with the best proven records. The CMS study estimated that the comparative
effectiveness research might cut national health spending by $8 billion over
the 2010-19 period. However, it doubted that the prevention and wellness programs
would reduce spending at all. Although these programs might diagnose diseases
in early stages and promote healthier lifestyles, they also mean "additional
costs [being] incurred as a result of increased screenings, preventive care,
and extended years of life."
The CMS study was requested by Rep. Dave
Camp of Michigan,
the ranking Republican member of the House
Ways and Means Committee. The study cautioned that
its forecasts were subject to much uncertainty, because the "the scope and
magnitude of the [proposed] changes are such that few precedents exist for use
in estimation." An earlier study by the Lewin Group, a health care consulting firm, also concluded that one of the major congressional proposals would increase national health spending. Lewin evaluated legislation passed by the House Energy and Commerce Committee and estimated that the bill would add $525 billion to national health spending in the 2010-2019 decade.